

NIFTY KEY LEVELS

Support 1 : 9820
Support 2 : 9700
Resistance1:10040
Resistance2:10160

Nifty Intraday Chart



Market Outlook

Yesterday, Nifty opened positive at 9880.85 and made a low of 9824.05. From there it moved towards the high of 9995.60 and closed positive at 9979.10 levels. Broader selling was seen in FMCG sector, while rest of the indices traded and closed with positive bias. India VIX closed negative by 2.43% at 29.99.

Domestic market shrugged off the negative downgrade rating of moody's and indices formed bullish candle while nifty end just shy of 10000 mark. The momentum oscillator RSI is started moving toward north side and daily MACD also started trading above signal line which has bullish implications. As long as nifty trades above 9820 followed by 9700, we expect nifty will continue its up move towards 10160-10200 levels after crossing above 100 DEMA which comes at 10040 levels.

Indian Market

Index (Prev. Close)	Value	% Change
SENSEX	33,825.53	1.57%
NIFTY	9,979.10	1.56%
BANK NIFTY	20,530.20	2.86%

Global Market

Index (Prev. Close)	Value	% Change
DOW	25,742.65	1.05%
NASDAQ	9,608.38	0.59%
CAC	4,858.97	2.02%
DAX	12,021.28	3.75%
FTSE	6,220.14	0.87%
EW ALL SHARE	16,719.15	1.23%

Morning Asian Market (8:30 am)

SGX NIFTY	10,076.00	0.97%
NIKKIE	22,685.50	1.61%
HANG SENG	24,254.00	1.08%

Commodity Market

Commodity(Prev. Close)	Value	% Change
GOLD	46,796.00	-0.61%
SILVER	49,080.00	-3.03%
CRUDEOIL	40.17	1.52%
NATURALGAS	134.70	-2.18%

Currency Market

Currency (Prev. Close)	Value	% Change
RS./DOLLAR	75.35	-0.25%
RS./EURO	84.13	0.03%
RS./POUND	94.41	0.78%

Bond Yield

Bond yield (Prev. Close)	Value	% Change
G-sec 10YR : IND	6.00	-0.73%

% Change in 1 day

Institutional Turnover

FII			
Investor	Buy(Cr.)	Sale(Cr.)	Net(Cr.)
02-Jun-20	12157	4659	7498
Jun-20	19172	10099	9074
2020	674129	740998	(66870)
DII			
Investor	Buy(Cr.)	Sale(Cr.)	Net(Cr.)
02-Jun-20	5066	4625	441
Jun-20	9957	9975	(18)
2020	522561	434934	87628

Events Today

Results

AUROPHARMA

BPCL

CHOLAFIN

DCMSHRIRAM

DENORA

DISAQ

DUNCANENG

LAKSELEC

ORIENTHOT

SRAMSET

TRABI

VESUVIUS

Dividend

TCS

Ex-Date: 03-06-2020

Please refer to page pg 07 for Bulk deals, Dividends, Bonus, Splits, Buyback.

Quote of the Day : "I would not pre-pay. I would invest instead and let the investments cover it"

GRANULES**ACCUMULATE****03-Jun-20**

GRANULES revenues declined by 2% in 4QFY20 on account of restriction imposed on export of Paracetamol API, PFI & FD's and disruption in logistics. Going ahead the management is confident of continued growth momentum based on increased contribution from higher-margin FDs, new product launches from GPI & contribution from Vizag API plant with higher margin products. Being vertically integrated, the company has the ability to manufacture & supply FDs with its own API, which has enabled the company to improve their gross margin. The company has been successful in managing the working capital cycle by reducing the working capital days from 118 days in FY19 to 104 days in FY20. The strategy going ahead would be to focus on the profitability through better capacity utilization and by enhancing product mix and operational cost efficiencies. Therefore, the long term prospects of the company look promising. We increase our rating from NEUTRAL to ACCUMULATE with a target price of Rs.201.

CEATLTD**NEUTRAL****02-Jun-20**

The overall OEMs demand scenario will continue to be under stress for next couple of quarters. Sharp decline in CV and PV was partially set off by strong growth in farm segment and 2-wheeler replacement market. The CV segment is expected to decline severely in the near term based on BS-VI price increase. Going ahead the replacement market is expected to remain buoyant based on shorter product lifecycle. The margin pressure is also expected to ease off based on the stabilizing commodity prices and improving product mix going ahead. Though higher depreciation and interest cost will keep the overall profitability under check. We largely maintain our FY21e estimates and value CEATLTD at 21x FY21e EPS to arrive at a target price of Rs.853 and maintain NEUTRAL.

LUPIN**NEUTRAL****02-Jun-20**

Lupin earnings in the last three years has remained impacted majorly due to higher price erosion in US, further the compliance issues worsened the situation for the company till FY19. The strategic divestment of Kyowa in Japan, impairment of Gavis & significant restructuring undertaken by the company in FY20 has significantly strengthened the balance sheet & profitability. Going ahead, the expected launch of Albuterol in 2HFY21, and ramp up in the Levothyroxine market share; we have a positive outlook for the US generic business. On the US branded business, the company has taken steps to optimize the Solosec spends as its prescription was impacted significantly due to the lockdown. The domestic sales will see some softness in Q1FY21 due to reduction in the prescription rate for the acute segment due to Covid'19 driven lockdown. As the key facilities gets cleared by the USFDA and cost reduction initiative undertaken by the company starts getting more visible in the books, we will have a clearer visibility. Post results, we have increased our PAT estimates for FY21 by 7% based on management ETR guidance of 34-35% in FY21. Therefore, we maintain our NEUTRAL stance with target price of Rs.842.

TVSMOTOR**NEUTRAL****29-May-20**

The automobile industry volumes are impacted for the period due to low demand sentiment, increased prices on account of BS VI and worsened by the recent COVID-19 outbreak. However, pickup in demand is expected from 2HFY21 considering the improvement in rural demand scenario, better monsoons and government's thrust on the revival of the overall economy. Going ahead, margins are expected to remain on the lower side due to higher BS-VI cost and weaker operating leverage despite reduction in commodity prices. We value standalone business at 19x FY21e EPS and TVS credit services at Rs.61 per share to arrive at a target price of Rs.400 and maintain NEUTRAL.

CREDITACC**BUY****02-Jun-20**

CREDITACC has shown resilient growth on the back of its strong rural presence. The growth has been mainly driven by the group loan segment. The margins have remained steady but there has been a spike in the GNPL levels. Management has commenced operations in 98% branches, Management remains optimistic about repayments from 70% of the customers. For moratorium 2.0 management envisage only 10% of the customers to be opting out. We expect higher credit costs going ahead as 30% of the customer are in red zones, however as the group meeting has been commenced with 1/4th of the attendance it will improve collections going ahead. CREDITACC is currently trading at 2x P/B at FY21e. We maintain BUY with a Target price of Rs 550.

- ❑ **Rating Changes Have Little Impact On Markets, Says CEA:** India's rating downgrade will have a little impact on the market as sovereign ratings are not a leading indicator, said Chief Economic Adviser (CEA), Krishnamurthy Subramanian. Speaking to CNBC-TV18, Subramanian said that the rating agencies have downgraded 33 countries since COVID-19 outbreak. The comment comes after the global credit rating agency Moody's Investors Services on Monday downgraded India's foreign-currency and local-currency long-term issuer ratings to Baa3 from Baa2. "Debt sustainability is not an issue in India as long as the GDP growth stays around 4 percent. We have analyzed the impact of rating changes over the last 20 years and found that rating changes are not a big event for markets. We should not be guided by rating action," Subramanian said.
- ❑ **Reliance Industries:** Bloomberg News reports that Abu Dhabi's Mubadala Investment is nearing a deal to invest about \$1 billion into Jio Platforms. An announcement could come as soon as this week. The company is also in discussions with Abu Dhabi Investment Authority & Saudi Arabia's The Public Investment Fund.
- ❑ **Lupin:** Gets U.S. FDA approval for its Meloxicam capsules. The company will market the generic equivalent of Vivlodex capsules of U.S. based Zyla Life Sciences, which are used for treatment of osteoarthritis pain.
- ❑ **Polycab India:** The company's CFO in an interaction with BloombergQuint said that Covid-19 impacted top-line numbers by Rs 600 crore and that they are cautious on domestic growth for the next two quarters. The company's cable and wire business saw a growth in market share despite the industry witnessing a 14% de-growth. It also expects the EPC segment to grow due to increase in demand of the optical fibre. The CFO also said that it has no significant exposure to China and that it has alternative arrangements with domestic suppliers.
- ❑ **Spandana Sphoorty Q4FY20** Calculated Interest Income up 28.4% to Rs 208.5 crore Net profit up 9.1% to Rs 77.5 crore Impairment on financial instruments rises to Rs 188 crore from Rs 21 crore All numbers are standalone and compared on a year-on-year basis.
- ❑ **InterGlobe Aviation Q4FY20** Revenue up 5.3% to Rs 8,299 crore - slowest growth since listing Net loss of Rs 873 crore from net profit of Rs 590 crore Ebitdar loss of Rs 13 crore from Ebitdar of Rs 2,056 crore Deferred tax credit of Rs 420 crore lowered the loss Net loss before tax of Rs 1,293 crore from net profit before tax of Rs 617 crore Lower passenger growth, passenger load factor, higher costs due to lockdown, weak rupee and high maintenance costs impacted earnings Forex loss of Rs 1,014 crore this quarter All numbers are standalone and compared on a year-on-year basis.
- ❑ **Britannia Q4FY20** Revenue up 2.5% to Rs 2,868 crore Net profit up 26.3% to Rs 375 crore Ebitda up 3.9% to Rs 454.5 crore Ebitda margin flat at 15.8% from 15.6% Gross margin down 150 basis points to 39.7% Raw Material costs down 1.2% to Rs 1,363 crore RM cost as a percentage of revenue at 47.5% from 49.3% Declares interim dividend of Rs 35 per share.
- ❑ **Hindustan Unilever:** The company was able to gradually improve the operations to 70 percent in April and has now increased production to 80-90 percent of normative levels.
- ❑ **Colgate-Palmolive India:** The company has resumed operations at all of its manufacturing plants. It believes that the impact of COVID-19 on its business operations on an annual basis may not be material.
- ❑ **Jubilant Foodworks:** The company said that the shutting of the dine-in format across all the stores will have a material impact on the performance of Q1FY21. Further, the company was able to open stores for delivery only in a staggered manner.
- ❑ **Havells India:** The company said that the lockdown has caused significant loss of production and sales in March and April. Recovery in revenues in the last few weeks have been encouraging especially in the non-metro cities, it said.

Red: Negative Impact **Green:** Positive Impact **Black :** Neutral.

ZYDUSWELL 4QFY20 concall Highlights:

- In Last 10 days of March company lost ~ Rs 100 cr worth of sales.
- Nutralite faced challenges as major portion of the business relies on Horeca while being personal care product, Everyuth was impacted relatively higher.
- Consolidated cash position stood at Rs 192.83 cr in FY20 including investment in liquid funds.
- Consolidated capex excluding Goodwill: Rs32.37 cr for the year.
- To expand sugar substitute category, the company has relaunched Sugar free green with improved formulation and packaging.
- As per MAT March 20 report of Nielsen, Nycil, Glucon D, Everyuth scrub and Everyuth peel off(Mask) has registered a market share of 34.4%, 59%, 32.5% and 77.9% with the category growth of 8.3%, 9.8%, 6.1% and 13.3% respectively.
- Company's product portfolio which is essential in nature contains: Sugar free, Complian, Glucon-D, and Nycil sanitizer.
- The company is planning to launch two new products in coming weeks, one each under Complian and Glucon-D.
- Management expects from June onwards normalcy in most of its categories.
- General trade and ecommerce (touching to ~3-3.5% of the overall business from nearly 1%) is doing better for the company.
- The company has stabilized its market share in Complian. Complian has witnessed good volume led growth in last 2 quarters. At present, its market share is ~5.4% (as Per MAT March 20 of Nielsen). HFD category grew by 10.7% in this quarter.
- Whole sale in back to normal in the most of part for the company while organised B2B is covering wherever wholesale is not present.
- The company is witnessing good recovery in demand and tier 2-3 cities are also responding better.
- The company will curtail ad spends significantly in Short term.
- At present, the company's Gross debt: Rs 1500 cr and Net debt: Rs 1300 cr
- Total coverage of the company: 1.7 to 2 mn outlets and 0.5 mn chemist reach in the urban India.
- Tax rate: Zero for the next 2-3 years.

GRANULES 4QFY20 Concall Highlights

- EBITDA grew by 25% adjusted for impairment taken for US pharma on account of increased capacity of Metformin commissioned last year, better FD margins, new product launches from GPI & contribution from Vizag API plant with higher margin products.
- The USFDA tested few samples of API & FDs of Metformin for NDMA content, the company has been recently communicated by the USFDA that the tested samples did not detect NDMA.
- The revenues from the top 5 core products reduced by 5% YoY due to restriction imposed on the export of API, PFI & FDs of Paracetamol, lockdown in the last week of March & increased contribution from the other products. The 5 core products contribute 85% of the total revenues.
- Post the upliftment of restriction from Paracetamol, the company sees significant increase in demand for Paracetamol & other products as well and have strong order book. The primary increase is expected to be seen in US products in terms of dispatches.
- The manufacturing capacities of the facilities are at 90-95%, with no supply disruption seen since March 2020.
- The gross margin improved from 45.9% in 4QFY19 to 53.5% in 4QFY20 on account of increased FDs share & launch of new products at GPI. EBITDA margin adjusted for the impairment increased by 440 bps YoY to 20.3%. The management expects the sustainable gross & EBITDA margins to be in the range of 50% & 20-21% respectively.
- The strategy of the company going ahead would be to focus on higher profitability with high margin products rather than chasing topline.
- The company expects to backward integrate all the products filed in the FD space which would improve the gross margins going ahead. Therefore, this Vizag API plant will be the next growth driver for the company.
- The company going ahead may invest into key intermediates to reduce its dependence on China.
- Buyback of shares is on track and is expected to be completed by the first week of July 2020.
- R&D in absolute terms is expected to remain stable. Along with FDs, R&D would be spent on APIs as well for making APIs more process efficient.

INDIGO Q4 FY-20 Concall Highlights

Financial Highlights

- ❑ In FY-20, INDIGO's Total income increased by 25% (Y-o-Y) to 37291 crores.
- ❑ For FY-20, INDIGO reported net loss of 234 crores compared to profit of 157 crores in FY-19.
- ❑ There was foreign currency loss of 1546 in FY-20, compared to 467 crores in FY-19.
- ❑ Impact of COVID-19
- ❑ Due to COVID, INDIGO's business was materially impacted as all operations were closed from 25-Mar till 24 May-20.
- ❑ Company has taken few measures to cut expenses like salary cut in the range of 5-25%, mandatory leave for May, June and July without pay. Also, company is in discussion with lessors to give them waiver for duration of lockdown period.

Operating Metrics

- ❑ In Q4FY-20
- ❑ ASK (billion) increased by 4.1% (Y-o-Y) to 23.
- ❑ Load Factor declined by 3.1% (Y-o-Y) to 82.8.
- ❑ Yield (INR) increased by 1% (Y-o-Y) to 3.74.
- ❑ RASK (INR) increased by 0.5% (Y-o-Y) to 3.65.

Liquidity Position

- ❑ Company has 20377 crores cash (including Restricted Cash) on books and Free cash of 8929 crores and company is targeting generate 3000-4000 more cash through cost cutting measures.

Impact of IND AS 116

- ❑ Due to adoption of Ind AS 116, PBT was negatively impacted by 953 and 1593 cores in Q4 and for full year FY-20 respectively.

Fleet Details

- ❑ As on Mar-20, Company has 262 Fleets (29 owned/finance Lease) and 233 operating lease. Company is replacing A320ceo flights with A321neo flights. As A321neo's flights require lesser maintenance expenses.

ATFL 4QFY20 Concall Highlights:

4QFY20 Highlights:

- ❑ The Company's food growth till 24-March-20 stood at 29% but ended up registering a growth of 18% YoY to Rs. 64 cr. In 4QFY20 due to COVID-19.
- ❑ The Company's ready to eat segment remained most impacted due to COVID-19 and declined by 13% YoY in 4QFY20 while down by 42% decline in QTD May-20 driven by retail contraction and choices in manufacturing (The Company choose to manufacture RTC).
- ❑ For FY20, revenue breakup for food business stood at 55% from RTC, 18% from RTE, 23% from spread, 2% from cereals and rest ~2% from vending business.
- ❑ Start-up of Unnao facility and Chittoor plants are pushed back due to some pending civil works.
- ❑ The Company currently has a market share of ~33% in Peanut butter.
- ❑ The Company has not witnessed any delay in payment from traditional channel on account of lockdown.
- ❑ As per the Company competitive intensity in peanut butter category is seen when the prices of peanut is very low.
- ❑ The Company will continue focussing on advancement in Ready to Cook segment and will come up with new launches in coming months.
- ❑ The Company's total reach stood at 400000 stores as of now while the largest distributed product is RTC popcorn.

Quarter to date highlights:

- ❑ All plants and warehouse of company are now open except those falling under containment zones.
- ❑ For the Company field sales functioning has improved as more retail stores are getting opened.
- ❑ Consumption trends in RTC, premium edible oil, chocolate spreads and breakfast cereals is improving with people staying indoors due to lockdown.
- ❑ The Company is witnessing moderate spreads growth due to lower Physical Fitness activities while chocolate spread is doing better.
- ❑ Lower out-of home or Impulse Purchase is negatively impacting Ready to Eat Snacks, Vending Business and Bulk Packs of Sundrop and Crystal Edible Oils.
- ❑ On QTD basis, Sundrop Cereals/ Sundrop Chocolate Confectionery contributed to the extent of 174 bps/74 bps of Foods Growth thus both products are doing well.
- ❑ The Company is currently witnessing increase in consumption of premium of edible oil as of 1QFY21 as a result of positive impact of mix and manufacturing choices.

Management Interview

EICHERMOT Management Interview (02 June, 2020):

- Commercial vehicle industry is going through a tough phase now. Industry sales have been only around 2,000 units which is lower by 90% of normal levels.
- Demand for new trucks is very low because only 35-40% trucks are operational on roads.
- Production is in line with sales for now as last quarter it produced 500 units and sold 686 units.
- Dealers are not getting fresh financing from banks if they already have taken moratorium. Similarly, customers are also facing same issue.

ESCORTS Management Interview (02 June, 2020):

- Tractor market will grow June onwards as there is a lot of pent up demand in the system.
- The company's 90% dealerships are open as of now.
- Dealers are facing financing issues, though there is no such issue on retail side.

BAJAJ-AUTO Management Interview (02 June, 2020):

- First half of May 2020 was almost washout period due to multiple regulations.
- Motorcycle demand is coming back in rural, agri and semi urban areas. The company is preparing itself for upto 70% of normal levels in the segment.
- The company will be having negative growth in 1HFY21, though 2HFY21 is expected to give small positive growth to the company.
- Three wheeler sales are lagging behind quite a bit.
- The company expect domestic retail demand to accelerate in June 2020.
- Commercial vehicle biz is at 30% of normalised levels
- All export orders could not be executed due to lower transport capacity, it is expecting to fulfil only 50% of export orders.
- The company has observed due to COVID-19, there is bit increase in 2 wheeler segment as people are preferring personal vehicles in this pandemic period.

BULK DEAL


EXCHANGE	Date	SECURITY CODE	CLIENT NAME	DEAL TYPE	QUANTITY	PRICE
BSE	02-06-20	ACEWIN	MEENAS	S	57,600	4.88
BSE	02-06-20	ADFFOODS	AUTHUM INVESTMENT & INFRASTRUCTURE LIMITED	B	40,684	275.11
BSE	02-06-20	ADFFOODS	ABAKKUS EMERGING OPPORTUNITIES FUND - 1	B	500,000	274
BSE	02-06-20	ADFFOODS	AUTHUM INVESTMENT & INFRASTRUCTURE LIMITED	S	500,000	274
BSE	02-06-20	COROMANDEL	E I D PARRY INDIA LIMITED	S	5,850,000	629.19
BSE	02-06-20	DIVINUS	AJITSHANKARRAONIKAM	S	57,217	38.5
BSE	02-06-20	DIVINUS	MANOJKUMAR GUNVANTRAI SOMANI	B	52,000	38.5
BSE	02-06-20	HITECHWIND	KEVIN MAHESHKUMAR SHAH	B	36,605	18.95
BSE	02-06-20	KILPEST	ALPHA LEON ENTERPRISES LLP	B	73,389	144.2
BSE	02-06-20	KILPEST	ALPHA LEON ENTERPRISES LLP	S	7,549	144.27
BSE	02-06-20	KOTAKBANK	UDAY SURESH KOTAK	S	56,000,000	1240
BSE	02-06-20	NEWLIGHT	MAHENDRA GANESHMAL AGRAWAL	B	15,000	35.87
BSE	02-06-20	NFIL	RUTANSHU BHASKARBHAI VYAS	B	40,000	10.83
BSE	02-06-20	NFIL	ASHA GAUTAMBHAI BORANA	S	40,000	10.83
BSE	02-06-20	SBRANDS	VINAY RUNGTA	B	67,000	4.52
BSE	02-06-20	SONAL	ORION PROPMART PRIVATE LIMITED	B	87,732	11.45
BSE	02-06-20	UPSURGE	AARTI MITESH JHUNJHUNWALA	S	460,670	8.71
BSE	02-06-20	UPSURGE	PRATIBHA DAYAKRISHNA GOYAL	B	573,244	8.71
BSE	02-06-20	VISVEN	VIJAY RASIKLAL SHAH	S	1,423	49.6
BSE	02-06-20	VISVEN	MUKESH KUMAR SUKHANI	B	1,405	48.94
BSE	02-06-20	VISVEN	SHREYA TRADERS	B	1,500	47.97

Corporate Action


EXCHANGE	SECURITY CODE	SECURITY NAME	EX- DATE	PURPOSE	RECORD DATE
BSE	500089	DICIND	04-06-20	Final Dividend - Rs. - 4.5000	-
BSE	532732	KKCL	04-06-20	Interim Dividend - Rs. - 6.0000	05-06-20

PARTICIPANT WISE OPEN INTEREST

Long Position




Short Position




MARKET MOVERS (1 MONTH CHANGE)

Nifty Movers



NSE Sectoral Indices Performance



Result Calendar Q4FY20

BSE Code	Company Name	Result Date	BSE Code	Company Name	Result Date
539570	ACEWIN	01-Jun-20	539725	GOKULAGRO	05-Jun-20
500060	BIRLACABLE	01-Jun-20	501455	GREAVESCOT	05-Jun-20
530879	CIFL	01-Jun-20	539336	GUJGAS	05-Jun-20
532459	FAZE3AUTO	01-Jun-20	503689	HEALINV	05-Jun-20
517449	MAGNAELQ	01-Jun-20	500183	HFCL	05-Jun-20
519494	NKIND	01-Jun-20	540702	LASA	05-Jun-20
541301	ORIENTELEC	01-Jun-20	500250	LGBBROSLTD	05-Jun-20
513605	SRIPIPES	01-Jun-20	500510	LT	05-Jun-20
506685	ULTRAMAR	01-Jun-20	531768	POLYMED	05-Jun-20
504212	UNIVCABLES	01-Jun-20	532934	PPAP	05-Jun-20
532953	VGUARD	01-Jun-20	504341	RELTD	05-Jun-20
517015	VINDHYATEL	01-Jun-20	532983	RPGLIFE	05-Jun-20
532553	WELENT	01-Jun-20	500112	SBIN	05-Jun-20
511601	YASHMGM	01-Jun-20	522113	TIMKEN	05-Jun-20
526433	ASMTEC	02-Jun-20	503671	UNIJOLL	05-Jun-20
500825	BRITANNIA	02-Jun-20	513375	CARBORUNIV	06-Jun-20
500119	DHAMPURSUG	02-Jun-20	542011	GRSE	06-Jun-20
505526	DOLAT	02-Jun-20	532652	KTKBANK	06-Jun-20
532482	GRANULES	02-Jun-20	533080	MOLDTKPAC	06-Jun-20
533177	IL&FSTRANS	02-Jun-20	530517	RELAXO	06-Jun-20
539448	INDIGO	02-Jun-20	517146	USHAMART	06-Jun-20
524404	MARKSANS	02-Jun-20	500488	ABBOTINDIA	08-Jun-20
517334	MOTHERSUMI	02-Jun-20	533167	COROENGG	08-Jun-20
500394	SOLCT	02-Jun-20	532702	GSPL	08-Jun-20
542759	SPANDANA	02-Jun-20	539353	SALAUTO	08-Jun-20
532872	SPARC	02-Jun-20	533248	GPPL	09-Jun-20
532349	TCI	02-Jun-20	500182	HEROMOTOCO	09-Jun-20
532371	TTML	02-Jun-20	500840	EIHOTEL	10-Jun-20
516072	VISHNU	02-Jun-20	533263	GREENPOWER	10-Jun-20
541400	ZIMLAB	02-Jun-20	501151	KARTKIN	10-Jun-20
531335	ZYDUSWELL	02-Jun-20	500089	DICIND	11-Jun-20
524804	AUROPHARMA	03-Jun-20	500403	SUNDRMFAST	11-Jun-20
500547	BPCL	03-Jun-20	500870	CASTROLIND	12-Jun-20
511243	CHOLAFIN	03-Jun-20	505200	EICHERMOT	12-Jun-20
523367	DCMSHRIRAM	03-Jun-20	524542	SUKHJITS	12-Jun-20
590031	DENORA	03-Jun-20	532893	VTMLTD	12-Jun-20
500068	DISAQ	03-Jun-20	533170	TAMBOLI	13-Jun-20
504908	DUNCANENG	03-Jun-20	504648	BOMBWIR	15-Jun-20
504258	LAKSELEC	03-Jun-20	504973	CHOLAHLDNG	15-Jun-20
500314	ORIENTHOT	03-Jun-20	538835	INTELLECT	15-Jun-20
531359	SRAMSET	03-Jun-20	500570	TATAMOTORS	15-Jun-20
526139	TRABI	03-Jun-20	541503	UNICK	15-Jun-20
520113	VESUVIUS	03-Jun-20	523160	MORGANITE	16-Jun-20
541269	CHEMFABALKA	04-Jun-20	532737	EMKAY	17-Jun-20
526227	FILATEX	04-Jun-20	532987	RBL	17-Jun-20
539174	HELPAE	04-Jun-20	532661	RML	18-Jun-20
517380	IGARASHI	04-Jun-20	500411	THERMAX	18-Jun-20
500304	NIITLTD	04-Jun-20	532988	RANEENGINE	19-Jun-20
523642	PIIND	04-Jun-20	516030	YASHPAKKA	20-Jun-20
523025	SAFARIND	04-Jun-20	508869	APOLLOHOSP	22-Jun-20
503806	SRF	04-Jun-20	514036	LOYALTEX	24-Jun-20
504959	STOVACQ	04-Jun-20	505800	RANEHOLDIN	24-Jun-20
533553	TDPOWERSYS	04-Jun-20	539447	BEARDSSELL	25-Jun-20
526650	TFCILTD	04-Jun-20	521161	SLSTLQ	25-Jun-20
539523	ALKEM	05-Jun-20	531737	GREENCREST	27-Jun-20
531489	CGVAK	05-Jun-20	535514	PRIMECAPM	27-Jun-20

Economic Calendar					
Country	Monday 01st June 2020	Tuesday 02nd June 2020	Wednesday 03rd June 2020	Thursday 04th June 2020	Friday 05th June 2020
US			API Weekly Crude Oil Stock, Crude Oil Inventories, Services PMI, Factory Orders	Initial Jobless Claims, Trade Balance	Nonfarm Payrolls, Unemployment Rate
UK/EUROPE	Manufacturing PMI		Services PMI/Unemployment Rate	ECB Interest Rate Decision	
INDIA	Manufacturing PMI		Services PMI		

Narnolia Financial Advisors Ltd. is a SEBI registered Research Analyst having SEBI Registration No. INH300006500. The Company/Analyst (s) does/do not have any holding in the stocks discussed but these stocks may have been recommended to clients in the past. Clients of Narnolia Financial Advisors Ltd. may be holding aforesaid stocks.

The stocks recommended are based on our analysis which is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed.

Disclosures: Narnolia Financial Advisors Ltd. (NFAL) (Formerly Microsec Capital Ltd.) is a SEBI Registered Research Analyst having registration no. INH300006500. NFAL is engaged in the business of providing Stock Broking, Depository Participant, Merchant Banking, Portfolio Management & distribution of various financial products. Details of associate entities of NFAL is available on the website at www.narnolia.com

No penalties have been levied on NFAL by any Regulatory/Statutory authority. NFAL, its associates, Research Analyst or their relative may have financial interest in the subject company. NFAL and/or its associates and/or Research Analyst may have beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report. NFAL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of NFAL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report. Research Analyst may have served as director/officer, etc. in the subject company in the last 12 month period. NFAL and/or its associates may have received compensation from the subject company in the past 12 months. In the last 12 months period ending on the last day of the month immediately preceding the date of publication of this research report, NFAL or any of its associates may have: a) managed or co-managed public offering of securities from subject company of this research report, b) received compensation for investment banking or merchant banking or brokerage services from subject company of this research report, c) received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report. d) Subject Company may have been a client of NFAL or its associates during 12 months preceding the date of distribution of the research report. NFAL and its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. NFAL and / or its affiliates may do and seek to do business including Investment Banking with companies covered in the research reports. As a result, the recipients of this report should be aware that NFAL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific Merchant Banking, Investment Banking or Brokerage service transactions. Research Analyst's views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of NFAL or its associates maintains arm's length distance with Research Team as all the activities are segregated from NFAL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Analyst Certification The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement-

Analyst's ownership of the stocks mentioned in the Report	NIL
---	-----

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com.

Correspondence Office Address: Arch Waterfront, 5th Floor, Block GP, Saltlake, Sector 5, Kolkata 700 091; Tel No.: 033-40541700; www.narnolia.com.

Registered Office Address: Marble Arch, Office 201, 2nd Floor, 236B, AIC Bose Road, Kolkata 700 020; Tel No.: 033-4050 1500; www.narnolia.com

Compliance Officer: Manish Kr Agarwal, Email Id: mkagarwal@narnolia.com, Contact No.:033-40541700.

Registration details of Company: Narnolia Financial Advisors Ltd. (NFAL): SEBI Stock Broker Registration: INZ000166737 (NSE/BSE/MSEI); NSDL/CDSL: IN-DP-380-2018; Research Analyst: INH300006500, Merchant Banking: (Registration No.: INM000010791), PMS: (Registration No.: INP000002304), AMFI Registered Mutual Fund distributor: ARN 3087

Registration Details of Group entities: G. Raj & Company Consultants Ltd (G RAJ)-BSE Broker INZ260010731; NSDL DP: IN-DP-NSDL-371-2014 || Narnolia Commerce Limited (Formerly Microsec Commerce Ltd.)-MCX/NCDEX Commodities Broker: INZ000051636 || NarnoliaVeloX Advisory Ltd.- SEBI Registered PMS: INP000005109 || Eastwind Capital Advisors Pvt Ltd. (EASTWIND)-SEBI Registered Investment Adviser: INA300005439 || Narnolia Insurance Brokers Limited (Formerly Microsec Insurance Brokers Ltd.)-IRDA Licensed Direct Insurance Broker (Life & Non-Life) Certificate No. 134, License No. DB046/02 || Narnolia Securities Ltd. (NSL)-AMFI Registered Mutual Fund distributor: ARN 20558, PFRDA NPS POP: 27092018 || Narnolia Capital Advisors Pvt. Ltd. - RBI Registered NBFC:B.05.02568.

Disclaimer:

This report has been prepared by Narnolia Financial Advisors Ltd. (NFAL) and is meant for sole use by the recipient and not for public circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of NFAL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his/her/its own advisors to determine the merits and risks of such an investment. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. NFAL will not treat recipients as customers by virtue of their receiving this report. Neither the Company, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits or lost opportunities that may arise from or in connection with the use of the information/report. The person accessing this information specifically agrees to exempt NFAL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold NFAL or any of its affiliates or employees responsible for any such misuse and further agrees to hold NFAL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NFAL & its group companies to registration or licensing requirements within such jurisdictions.